Study Finds a Worrying New Side Effect of GLP-1 Drugs That No One's Talking About - ScienceAlert

What the report says

ScienceAlert reported on July 23, 2026, that a new BMJ study has identified a possible association between GLP-1 receptor agonist drugs and hair loss among people with type 2 diabetes. The medications, which include widely used brands such as Wegovy and Ozempic, are prescribed for diabetes management and, in some cases, weight loss. Researchers led by a University of Pennsylvania team compared GLP-1 users with patients taking two other diabetes drug classes: SGLT-2 inhibitors and DPP-4 inhibitors.

According to the article, the study found a higher recorded risk of alopecia among GLP-1 users: 37% higher compared with SGLT-2 inhibitors and 68% higher compared with DPP-4 inhibitors. The finding was focused on non-scarring alopecia, a form of hair loss that may be reversible. The analysis included more than 12,000 GLP-1 users in each comparison group and accounted for factors such as age, sex, ethnicity and existing health conditions.

ScienceAlert noted that the absolute risk remained low: about seven cases per 1,000 people within a year among GLP-1 users, compared with roughly five per 1,000 for SGLT-2 users and four per 1,000 for DPP-4 users. The researchers suggested that rapid weight loss or nutritional changes, including iron or zinc deficiency, could be possible contributors, but said more work is needed to clarify the mechanism.

The report also emphasized limitations: medical records did not fully capture how severe or long-lasting the hair loss was, or whether it resolved. The findings add to ongoing evaluation of GLP-1 benefits and risks, and may help doctors and patients discuss treatment choices.